A Phase 4 interventional study of linezolid in Gram-Positive Bacterial Infections and Skin and Connective Tissue Diseases, sponsored by Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-10.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
To assess the onset of action of linezolid
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 118 is close to the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Time to defervescence
Reduction of CRP levels Reduction of leucocyte count
No study locations are listed for this record.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer